|Bid||16.90 x 3000|
|Ask||17.13 x 1100|
|Day's Range||16.61 - 18.15|
|52 Week Range||9.78 - 25.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2017 - Mar 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.50|
Spectrum Pharmaceuticals (SPPI) is a biotechnology company focused on advancing its late-stage investigational drugs, such as poziotinib, eflapegrastim, and apaziquone, to address unmet need across multiple oncology indications. Spectrum Pharmaceuticals has reported a YTD (year-to-date) return of 12.72% in 2018. Analysts have projected a 12-month consensus target price of $34.5 for Spectrum, which is 61.52% higher than its closing price on September 21.
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced preliminary poziotinib data from the University of Texas, MD Anderson Cancer Center Phase 2 non-small cell lung cancer (NSCLC) study which were released today during an oral presentation at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. The MD Anderson study is the single largest data set of patients with an exon 20 mutation in EGFR or HER2.
Small-cap stocks are considered riskier than large caps or even mid caps. Of course, this means that smaller stocks have greater potential to make profits for investors. This does not mean that you should buy risky stocks randomly.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) with a market-capitalization of US$2.22b, rarely draw their attention. While they are lessRead More...
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has initiated two new cohorts for first-line, locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR or HER2 exon 20 insertion mutations in its current Phase 2 non-small cell lung cancer (NSCLC) clinical trial. Spectrum also announced that it has dosed the first patient in the expanded patient population.
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.
On September 6, Spectrum Pharmaceuticals stock closed at $22.25, which is a ~5.70% rise from its close of $21.05 on September 5, 2018. On September 6, Spectrum Pharmaceuticals stock price closed at $22.25, which represents ~146% growth from its 52-week low of $9.03 on September 22, 2017. Spectrum Pharmaceuticals hit its 52-week high of $25.29 on August 27, 2018.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 5) Aptinyx Inc (NASDAQ: APTX ) Avanos Medical Inc (NYSE: AVNS ...
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average ...
HENDERSON, Nev.-- -- The abstract reported new interim data from the EGFR cohort and, for the first time, the HER2 cohort in the MD Anderson Phase 2 trial In the EGFR cohort, an objective response rate of 58% and a disease control rate of 90% were reported In the HER2 cohort, an objective response rate of 50% and a disease control rate of 83% were reported Updated data will be presented in an oral ...
The biotech sector notched strong gains last week, capitalizing on the positive overall market sentiment, set in motion by the trade deal between the U.S. and Mexico. Here are a few catalysts that could ...
Investors in Spectrum Pharmaceuticals (SPPI) need to pay close attention to the stock based on moves in the options market lately.
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of International ...
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at two upcoming conferences being held in New York on September 5th and September 6th. The presentations will be webcast live and may be accessed by visiting Spectrum’s website at http://investor.sppirx.com/events-and-presentations. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
Avant Diagnostics, Inc. ("Avant" or the “Company”) (OTC Pink: AVDX), today announced the addition of two internationally known oncology experts, Dr. Rajesh Shrotriya, M.D. and Andy DeLaO, to its Board of Directors, the appointments to be effective on Tuesday, August 28, 2018. Dr. Rajesh Shrotriya, M.D., the former CEO and Chairman of Spectrum Pharmaceuticals (NASDAQ: SPPI), has over four decades of experience in the medical field, first as a dedicated physician and then as a pharmaceutical industry executive.
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / U.S. equities plunged on Friday as rising currency crisis in Turkey fueled a global market pullback. The Turkish lira is down 20 percent this week, slumping ...
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of -16.67% and -13.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Henderson, Nevada-based company said it had profit of 13 cents. Losses, adjusted for one-time gains and costs, came to 21 cents per share. The biotechnology company posted revenue ...
HENDERSON, Nev.-- -- An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto Spectrum’s current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent conversations with the FDA Both Phase 3 ROLONTIS ® studies, RECOVER and ADVANCE, ...